Research programme: antibacterial nanotherapeutics - Techulon
Latest Information Update: 28 Oct 2024
At a glance
- Originator Techulon
- Class Antibacterials; Peptide nucleic acids
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acinetobacter infections; Gram-negative infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for research development in Acinetobacter-infections in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for research development in Gram-negative-infections in USA (Parenteral)